Patents by Inventor Qiaobing Xu

Qiaobing Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10888622
    Abstract: A nanocomplex containing a delivery agent and a pharmaceutical agent. The nanocomplex has a particle size of 50 to 1000 nm, the delivery agent binds to the pharmaceutical agent via non-covalent interaction or covalent bonding, and the pharmaceutical agent is a modified peptide or protein formed of a peptide or protein and an added chemical moiety that contains an anionic group, a disulfide group, a hydrophobic group, a pH responsive group, a light responsive group, a reactive oxygen species responsive group, or a combination thereof.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: January 12, 2021
    Assignee: Trustees of Tufts College
    Inventors: Qiaobing Xu, Ming Wang
  • Publication number: 20200405639
    Abstract: The disclosure includes non-naturally occurring or engineered CRISPR systems and proteins, associated with a delivery system comprising a virus component and a lipid component. The disclosure includes CRISPR proteins associated with capsid proteins, e.g., AAV VP!, VP2, and/or VP3, on the surface of or internal to the AAV, along with compositions, systems and complexes involving the AAV-CRISPR protein, nucleic acid molecules and vectors encoding the same, deliver}-systems, and uses therefor.
    Type: Application
    Filed: April 16, 2018
    Publication date: December 31, 2020
    Inventors: Feng Zhang, Sourav Choudhury, Qiaobing Xu
  • Publication number: 20200368254
    Abstract: Disclosed are compounds of formula (I) below: wherein each of the variables A, B, X, W, V, R1-R5, and m are defined herein. Also disclosed are pharmaceutical compositions containing a nanocomplex, wherein the nanocomplex is formed of one of the compounds, and a protein, a nucleic acid, or a small molecule; and methods of treating a medical condition with one of the pharmaceutical compositions.
    Type: Application
    Filed: February 1, 2019
    Publication date: November 26, 2020
    Inventors: Qiaobing Xu, Yamin Li
  • Patent number: 10792328
    Abstract: A nanocomplex, of particle size 50 nm to 1000 nm, containing saporin and a lipid-like compound, in which saporin binds to the lipid-like compound via non-covalent interaction or covalent bonding. The lipid-like compound has a hydrophilic moiety, a hydrophobic moiety, and a linker joining the hydrophilic moiety and the hydrophobic moiety. The hydrophilic moiety is optionally charged and the hydrophobic moiety has 8 to 24 carbon atoms. Also disclosed is a pharmaceutical composition containing such a nanocomplex and a pharmaceutically acceptable carrier. The nanocomplex is useful in treating diseases, such as cancer.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: October 6, 2020
    Assignee: Trustees of Tufts College
    Inventors: Qiaobing Xu, Ming Wang
  • Publication number: 20190381189
    Abstract: A nanocomplex, 50 to 1000 nm in size, containing a lipid-like nanoparticle formed of a cationic lipid-based compound and a modified protein formed of a protein and an anionic polymer that includes a plurality of polar groups, the lipid-like nanoparticle and the modified protein being non-covalently bonded to each other. Also disclosed are a method of preparing the above-described nanocomplex and use thereof for treating a medical condition. Further disclosed is a pharmaceutical composition containing a nanocomplex.
    Type: Application
    Filed: January 23, 2018
    Publication date: December 19, 2019
    Inventor: Qiaobing Xu
  • Publication number: 20190270822
    Abstract: An antibody-conjugated nanoparticle, 50 to 1000 nm in size, containing an anti-Mullerian hormone receptor II (AMHRII) antibody that is conjugated to a nanocomplex formed of a lipid-based delivery agent and a cytotoxin, the delivery agent and the cytotoxin being non-covalently bonded to each other. Also disclosed are a method of preparing such an antibody-conjugated nanoparticle and use thereof for inducing sterilization in a subject and for treating an AMHRII-associated condition.
    Type: Application
    Filed: July 11, 2017
    Publication date: September 5, 2019
    Inventors: Sandra L. Ayres, Qiaobing Xu, Kristy L. Meadows
  • Publication number: 20190240288
    Abstract: A nanocomplex, of particle size 50 nm to 1000 nm, containing saporin and a lipid-like compound, in which saporin binds to the lipid-like compound via non-covalent interaction or covalent bonding. The lipid-like compound has a hydrophilic moiety, a hydrophobic moiety, and a linker joining the hydrophilic moiety and the hydrophobic moiety. The hydrophilic moiety is optionally charged and the hydrophobic moiety has 8 to 24 carbon atoms. Also disclosed is a pharmaceutical composition containing such a nanocomplex and a pharmaceutically acceptable carrier. The nanocomplex is useful in treating diseases, such as cancer.
    Type: Application
    Filed: January 15, 2019
    Publication date: August 8, 2019
    Inventors: Qiaobing Xu, Ming Wang
  • Patent number: 9765022
    Abstract: A compound of formula the following formula: (I). In this formula, moieties A, B, X, R1, R2, and R3 are defined herein. Also disclosed are a nanocomplex that is formed of such a compound and a pharmaceutical agent, and a nanocomplex that is formed of a protein and a bioreducible compound.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: September 19, 2017
    Assignee: Tufts University
    Inventors: Qiaobing Xu, Ming Wang
  • Publication number: 20160129120
    Abstract: A nanocomplex containing a delivery agent and a pharmaceutical agent. The nanocomplex has a particle size of 50 to 1000 nm, the delivery agent binds to the pharmaceutical agent via non-covalent interaction or covalent bonding, and the pharmaceutical agent is a modified peptide or protein formed of a peptide or protein and an added chemical moiety that contains an anionic group, a disulfide group, a hydrophobic group, a pH responsive group, a light responsive group, a reactive oxygen species responsive group, or a combination thereof.
    Type: Application
    Filed: May 13, 2014
    Publication date: May 12, 2016
    Inventors: Qiaobing XU, Ming WANG
  • Publication number: 20160082126
    Abstract: A nanocomplex, of particle size 50 nm to 1000 nm, containing saporin and a lipid-like compound, in which saporin binds to the lipid-like compound via non-covalent interaction or covalent bonding. The lipid-like compound has a hydrophilic moiety, a hydrophobic moiety, and a linker joining the hydrophilic moiety and the hydrophobic moiety. The hydrophilic moiety is optionally charged and the hydrophobic moiety has 8 to 24 carbon atoms. Also disclosed is a pharmaceutical composition containing such a nanocomplex and a pharmaceutically acceptable carrier. The nanocomplex is useful in treating diseases, such as cancer.
    Type: Application
    Filed: May 13, 2014
    Publication date: March 24, 2016
    Inventors: Qiaobing Xu, Ming Wang
  • Publication number: 20160053231
    Abstract: A microfabricated multi-tissue system for in vitro drug toxicity testing having a plurality of layers, each of which is formed of decellularized tissue extracellular matrix (ECM) including parenchymal cells and non-parenchymal cells attached thereto. Also disclosed is a method for producing a decellularized ECM paste, and methods for producing an ECM construct and a porous 3-D scaffold from the decellularized ECM paste.
    Type: Application
    Filed: April 9, 2014
    Publication date: February 25, 2016
    Inventor: Qiaobing Xu
  • Publication number: 20160009643
    Abstract: A compound of formula the following formula: (I). In this formula, moieties A, B, X, R1, R2, and R3 are defined herein. Also disclosed are a nanocomplex that is formed of such a compound and a pharmaceutical agent, and a nanocomplex that is formed of a protein and a bioreducible compound.
    Type: Application
    Filed: February 28, 2014
    Publication date: January 14, 2016
    Inventors: Qiaobing Xu, Ming Wang
  • Patent number: 8529784
    Abstract: Methods and apparatuses for generating electrically-conductive and/or semi-conductive films, and more specifically, methods and apparatuses for generating conductive and/or semi-conductive films having nanoscale features are provided. In one embodiment, an electrically-conductive or semi-conductive film (e.g., a gold layer of less than 50 nanometer thickness) is provided on a substrate (e.g., a poly(dimethylsiloxane) (PDMS) stamp). The substrate may optionally include patterns or features having raised and recessed portions. A first portion of the film may be removed from the substrate, e.g., by methods such as physically contacting the first portion of the film with a surface to which the first portion preferentially adheres. This process can leave a second portion of the film remaining on the substrate. In some embodiments, the second portion includes at least one region having a dimension substantially parallel to a portion of the substrate i.e., of less than 50 nanometers.
    Type: Grant
    Filed: August 9, 2006
    Date of Patent: September 10, 2013
    Assignee: President and Fellows of Harvard College
    Inventors: Tingbing Cao, Qiaobing Xu, Adam Winkleman, George M. Whitesides
  • Publication number: 20090295364
    Abstract: Methods and apparatuses for generating electrically-conductive and/or semi-conductive films, and more specifically, methods and apparatuses for generating conductive and/or semi-conductive films having nanoscale features are provided. In one embodiment, an electrically-conductive or semi-conductive film (e.g., a gold layer of less than 50 nanometer thickness) is provided on a substrate (e.g., a poly(dimethylsiloxane) (PDMS) stamp). The substrate may optionally include patterns or features having raised and recessed portions. A first portion of the film may be removed from the substrate, e.g., by methods such as physically contacting the first portion of the film with a surface to which the first portion preferentially adheres. This process can leave a second portion of the film remaining on the substrate. In some embodiments, the second portion includes at least one region having a dimension substantially parallel to a portion of the substrate i.e., of less than 50 nanometers.
    Type: Application
    Filed: August 9, 2006
    Publication date: December 3, 2009
    Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Tingbing Cao, Qiaobing Xu, Adam Winkleman, Geroge M. Whitesides